Needham Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $100
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Express News | Intra-Cellular Therapies Inc : Needham Raises Target Price to $100 From $94
Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $92
Morgan Stanley Remains a Buy on Intra-Cellular Therapies (ITCI)
BofA Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating
RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $107
Intra-Cellular Therapies (ITCI) Receives a Buy From RBC Capital
Express News | Intra-Cellular Therapies Inc : RBC Raises Target Price to $107 From $103
When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Become Profitable?
Unusual Options Activity: APA, GNRC and Others Attract Market Bets, APA V/OI Ratio Reaches 868.8
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Intra-Cellular Therapies(ITCI.US) Director Sells US$337.19K in Common Stock
Intra-Cellular Therapies Cut to Neutral From Buy by UBS
UBS Downgrades Intra-Cellular Therapies(ITCI.US) to Hold Rating, Raises Target Price to $83
RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $103
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Intra-Cellular Therapies(ITCI.US) Director Sells US$1.52 Million in Common Stock